182 related articles for article (PubMed ID: 25190543)
1. Treatment of Aspergillus terreus infections: a clinical problem not yet resolved.
Pastor FJ; Guarro J
Int J Antimicrob Agents; 2014 Oct; 44(4):281-9. PubMed ID: 25190543
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetics and pharmacodynamics of antifungal drugs in children].
Jullien V
Arch Pediatr; 2011 May; 18 Suppl 1():S42-7. PubMed ID: 21596286
[TBL] [Abstract][Full Text] [Related]
4. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.
Sutton DA; Sanche SE; Revankar SG; Fothergill AW; Rinaldi MG
J Clin Microbiol; 1999 Jul; 37(7):2343-5. PubMed ID: 10364610
[TBL] [Abstract][Full Text] [Related]
5. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
6. Experimental efficacy of anidulafungin against Aspergillus terreus species complex.
Sanchis M; Capilla J; Mayayo E; Pastor FJ; Guarro J
Med Mycol; 2015 Aug; 53(6):630-5. PubMed ID: 25980004
[TBL] [Abstract][Full Text] [Related]
7. Antifungal PK/PD considerations in fungal pulmonary infections.
Lepak AJ; Andes DR
Semin Respir Crit Care Med; 2011 Dec; 32(6):783-94. PubMed ID: 22167406
[TBL] [Abstract][Full Text] [Related]
8. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
9. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
[TBL] [Abstract][Full Text] [Related]
10. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies.
Hachem RY; Kontoyiannis DP; Boktour MR; Afif C; Cooksley C; Bodey GP; Chatzinikolaou I; Perego C; Kantarjian HM; Raad II
Cancer; 2004 Oct; 101(7):1594-600. PubMed ID: 15378491
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience.
Lass-Flörl C; Griff K; Mayr A; Petzer A; Gastl G; Bonatti H; Freund M; Kropshofer G; Dierich MP; Nachbaur D
Br J Haematol; 2005 Oct; 131(2):201-7. PubMed ID: 16197450
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic implications for use of antifungal agents.
Lewis RE
Curr Opin Pharmacol; 2007 Oct; 7(5):491-7. PubMed ID: 17616480
[TBL] [Abstract][Full Text] [Related]
13. Combination antifungal therapy for invasive fungal infections in children and adults.
Hatipoglu N; Hatipoglu H
Expert Rev Anti Infect Ther; 2013 May; 11(5):523-35. PubMed ID: 23627858
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of amphotericin B and micafungin combination against clinical isolates of Aspergillus species.
Nishi I; Sunada A; Toyokawa M; Asari S; Iwatani Y
J Chemother; 2011 Apr; 23(2):102-6. PubMed ID: 21571627
[TBL] [Abstract][Full Text] [Related]
15. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus.
Chamilos G; Kontoyiannis DP
Drug Resist Updat; 2005 Dec; 8(6):344-58. PubMed ID: 16488654
[TBL] [Abstract][Full Text] [Related]
16. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.
Lass-Flörl C; Kofler G; Kropshofer G; Hermans J; Kreczy A; Dierich MP; Niederwieser D
J Antimicrob Chemother; 1998 Oct; 42(4):497-502. PubMed ID: 9818749
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
Seyedmousavi S; Mouton JW; Verweij PE; Brüggemann RJ
Expert Rev Anti Infect Ther; 2013 Sep; 11(9):931-41. PubMed ID: 24053274
[TBL] [Abstract][Full Text] [Related]
18. [Progress in combination therapy for invasive aspergillosis].
Luo L; Tong Z
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jan; 37(1):41-4. PubMed ID: 24694973
[No Abstract] [Full Text] [Related]
19. In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.
Katragkou A; McCarthy M; Meletiadis J; Petraitis V; Moradi PW; Strauss GE; Fouant MM; Kovanda LL; Petraitiene R; Roilides E; Walsh TJ
Antimicrob Agents Chemother; 2014 Nov; 58(11):6934-7. PubMed ID: 25136021
[TBL] [Abstract][Full Text] [Related]
20. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]